SCHEMBL16666781

SCHEMBL16666781

CCCCCCOC(=O)C(Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UBASH3B Q8TF42 1/20 0.69
▸ CCKBR P32239 2/20 0.54
▸ TACR1 P25103 5/20 0.51
▸ KDM4E B2RXH2 3/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ TSHR P16473 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ CCKAR P32238 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ TP53 P04637 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ F11 P03951 1/20 0.45
▸ PTGS2 P35354 1/20 0.45
▸ IL1RN P18510 1/20 0.43
▸ ERAP2 Q6P179 1/20 0.43
▸ ERAP1 Q9NZ08 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23280197 0.90 UBASH3B (0.69) UBASH3BCCKBRTACR1KDM4EALDH1A1
SCHEMBL16666451 0.89 UBASH3B (0.74) UBASH3BCCKBRTACR1KDM4EALDH1A1
SCHEMBL16666555 0.89 UBASH3B (0.76) UBASH3BCCKBRTACR1KDM4EALDH1A1
SCHEMBL16666493 0.89 UBASH3B (0.68) UBASH3BCCKBRTACR1KDM4EALDH1A1
SCHEMBL16666561 0.88 UBASH3B (0.72) UBASH3BCCKBRTACR1KDM4EALDH1A1
SCHEMBL16666431 0.88 UBASH3B (0.75) UBASH3BCCKBRTACR1KDM4EALDH1A1
SCHEMBL16666556 0.88 UBASH3B (0.71) UBASH3BCCKBRTACR1KDM4EALDH1A1
SCHEMBL16666780 0.88 UBASH3B (0.71) UBASH3BCCKBRTACR1KDM4EALDH1A1
SCHEMBL16666247 0.87 UBASH3B (0.74) UBASH3BCCKBRTACR1KDM4EALDH1A1
SCHEMBL16666855 0.87 UBASH3B (0.79) UBASH3BCCKBRTACR1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF ASTECH. CO., LTD. (KR) 2015-05-21 — — US claimed
EP-2865669-A1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2015-04-29 — — EP claimed
US-11420963-B2 Rebamipide prodrugs, preparation method and use thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2022-08-23 — — US disclosed
EP-2865669-B1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF SAMJIN PHARM CO LTD (KR) 2021-04-28 — — EP disclosed
EP-2865669-B1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF SAMJIN PHARM CO LTD (KR) 2021-04-28 — — EP disclosed
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF ASTECH. CO., LTD. (KR) 2015-05-21 — — US disclosed
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF ASTECH. CO., LTD. (KR) 2015-05-21 — — US disclosed
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF ASTECH. CO., LTD. (KR) 2015-05-21 — — US disclosed
EP-2865669-A1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2015-04-29 — — EP disclosed
EP-2865669-A1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2015-04-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF REV1, GRPR, SI UBASH3B 2690/4885CCKBR 36/4885TACR1 2155/4885
US-11420963-B2 Rebamipide prodrugs, preparation method and use thereof SI, CYP2A7, MLN UBASH3B 3043/4885CCKBR 32/4885TACR1 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback